Free tool
FAERS Monitor: Tykerb
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022059 or its brand name (Tykerb, Lapatinib Ditosylate). Reports on generic versions are filed under their own applications.
Reports
15,452
Serious
10,580
68% of reports
Hospitalization
4,015
Death reported
2,486
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea4,173
- nausea1,616
- death1,463
- fatigue1,309
- vomiting1,211
- rash1,062
- disease progression1,007
- palmar-plantar erythrodysaesthesia syndrome931
- asthenia607
- malignant neoplasm progression565
- drug ineffective561
- dyspnoea561
- pyrexia528
- dehydration525
- decreased appetite519
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 9 |
| 2006 | 14 |
| 2007 | 936 |
| 2008 | 744 |
| 2009 | 1,056 |
| 2010 | 1,246 |
| 2011 | 1,667 |
| 2012 | 1,539 |
| 2013 | 1,479 |
| 2014 | 1,035 |
| 2015 | 1,102 |
| 2016 | 532 |
| 2017 | 721 |
| 2018 | 635 |
| 2019 | 674 |
| 2020 | 706 |
| 2021 | 356 |
| 2022 | 240 |
| 2023 | 253 |
| 2024 | 297 |
| 2025 | 145 |
| 2026 | 66 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,038,707 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| palmar-plantar erythrodysaesthesia syndromeSignal | 931 | 56.6 | 53.1 | 48,800 |
| disease progressionSignal | 1,007 | 11.7 | 11.0 | 9,790 |
| diarrhoeaSignal | 4,173 | 8.9 | 8.6 | 29,776 |
| malignant neoplasm progressionSignal | 565 | 7.5 | 7.0 | 3,200 |
| dehydrationSignal | 525 | 5.4 | 4.9 | 1,870 |
| vomitingSignal | 1,211 | 3.5 | 3.3 | 2,218 |
| rashSignal | 1,062 | 3.3 | 3.1 | 1,753 |
| decreased appetiteSignal | 519 | 3.0 | 2.8 | 718 |
| nauseaSignal | 1,616 | 2.8 | 2.7 | 1,912 |
| deathSignal | 1,463 | 2.3 | 2.2 | 1,135 |
| fatigueSignal | 1,309 | 2.3 | 2.2 | 986 |
| astheniaSignal | 607 | 2.2 | 2.0 | 402 |
| pyrexiaSignal | 528 | 2.1 | 1.9 | 299 |
| dyspnoea | 561 | 1.3 | 1.2 | 52 |
| drug ineffective | 561 | 0.6 | 0.5 | 182 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.